We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

152 hedge funds and large institutions have $329M invested in PDL BioPharma, Inc. in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 56 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

476% more call options, than puts

Call options by funds: $334K | Put options by funds: $58K

11% more capital invested

Capital invested by funds: $297M → $329M (+$31.9M)

7% less funds holding

Funds holding: 163 → 152 (-11)

30% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 56

40% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 25

Holders
152
Holders Change
-11
Holders Change %
-6.75%
% of All Funds
3.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
39
Reduced
56
Closed
25
Calls
$334K
Puts
$58K
Net Calls
+$276K
Net Calls Change
+$359K

Top Buyers

Rank Fund Capital Flow
1
KCM
Kennedy Capital Management
Missouri
+$13.1M
2
BIP
Brandes Investment Partners
California
+$8.99M
3
AC
Armistice Capital
New York
+$4.42M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.19M
5
Citadel Advisors
Citadel Advisors
Florida
+$2.09M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$6.65M
2
BlackRock
BlackRock
New York
-$3.69M
3
AQR Capital Management
AQR Capital Management
Connecticut
-$3.43M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.17M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$2.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
EMG
151
ETF Managers Group
New Jersey
– -$733 -255,315 Closed
AIM
152
Alambic Investment Management
California
– -$382K -163,200 Closed
SCP
153
Seizert Capital Partners
Michigan
– -$476K -161,998 Closed
PAM
154
Panagora Asset Management
Massachusetts
– -$330K -140,847 Closed
Susquehanna International Group
155
Susquehanna International Group
Pennsylvania
– -$286K -116,523 Closed
ECM
156
Element Capital Management
New York
– -$244K -104,080 Closed
BCM
157
BTC Capital Management
Iowa
– -$225K -96,218 Closed
FA
158
Fortis Advisors
Pennsylvania
– -$107K -45,602 Closed
CANY
159
Caxton Associates (New York)
New York
– -$105K -45,069 Closed
WA
160
WealthTrust Axiom
Pennsylvania
– -$79K -34,000 Closed
CB
161
Cadence Bank
Mississippi
– -$51K -21,800 Closed
Simplex Trading
162
Simplex Trading
Illinois
– -$50.6K -20,607 Closed
Wolverine Trading
163
Wolverine Trading
Illinois
– -$53K -17,903 Closed
SBIA
164
Sheaff Brock Investment Advisors
Indiana
– -$30K -13,018 Closed
TSS
165
Two Sigma Securities
New York
– -$30K -12,985 Closed
ZCA
166
Zeke Capital Advisors
Pennsylvania
– -$28K -12,071 Closed
FQ
167
First Quadrant
California
– -$23K -9,813 Closed
RA
168
Royce & Associates
New York
– -$19K -8,036 Closed
PIA
169
Piedmont Investment Advisors
North Carolina
– -$6K -2,579 Closed
IF
170
Ironwood Financial
Arizona
– -$3K -1,150 Closed
CMBA
171
C.M. Bidwell & Associates
Hawaii
– -$3K -1,120 Closed
Envestnet Asset Management
172
Envestnet Asset Management
Illinois
– -$1K -704 Closed
SWM
173
Selective Wealth Management
Virginia
– +$344 +140 New
3 4 5 6
7

PDLI Hedge Fund Activity: Q3 2018 in Review

152 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2018, worth a combined $329M — up 11% from $297M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of PDLI and 15 opened new positions — a net loss of 10 holders — while 56 trimmed existing stakes and 39 added.

The largest buyer was Kennedy Capital Management, adding an estimated $13.1M. The largest seller was Vanguard Group, cutting an estimated $6.65M.

  • 152 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2018, down from 163 in Q2 2018.
  • Funds reported $329M of PDL BioPharma, Inc. stock for Q3 2018, up 11% quarter-over-quarter.
  • 15 funds opened new PDL BioPharma, Inc. positions in Q3 2018 and 25 closed out, a net change of -10 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2018 was Kennedy Capital Management, an estimated $13.1M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2018 was Vanguard Group, an estimated $6.65M sold.

Based on aggregated 13F filings for Q3 2018.